Revvity Inc. stock (US76155R1086): insider activity and recent trading in focus

Shares of Revvity, the U.S.-listed life sciences and diagnostics group, recently changed hands close to USD 100 on the New York Stock Exchange as investors followed a steady news flow on operations and governance, including insider transactions and ownership disclosures filed with the U.S. Securities and Exchange Commission.

The stock traded at about USD 101 on NYSE under the ticker RVTY in the latest session, with a 52-week range roughly between USD 81 and USD 118 according to exchange data and price services as of late May 2026, underscoring that the share price has recovered from last year's lows but remains below the recent high set earlier in the current 12-month period.

Revvity is headquartered in Waltham, Massachusetts in the United States, and the primary listing for the company is on the New York Stock Exchange in U.S. dollars, which anchors the home-country perspective for investors monitoring corporate developments, regulatory filings and liquidity in the core U.S. market.

In parallel with the NYSE quotation, the stock can also be accessed by German investors via secondary trading venues such as Tradegate or Frankfurt in euro, though volumes typically concentrate in the home U.S. market where institutional participation and analyst coverage are strongest.

While there has not been a major price-shifting corporate announcement in the immediate past days, the company continues to publish operational updates, job postings and other business-related information through its corporate website and investor communication channels, reflecting an ongoing focus on life sciences tools, diagnostics and laboratory technologies serving research and clinical customers.

Regulatory filings in the United States remain a key information source for shareholders, as Form 4 insider trading reports and Schedule 13 filings on significant holdings offer insight into the behavior of executives, directors and large institutional owners in the period following the company's strategic repositioning and brand transition to the Revvity name.

Against this backdrop of normal trading and ongoing disclosure, investors pay particular attention to any sizeable equity transactions by top management or major shareholders, which can signal confidence, diversification or portfolio rebalancing, though such moves always require careful interpretation in the broader context of company fundamentals and sector trends.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Revvity Inc.: core business model

Revvity focuses on providing life sciences research tools and clinical diagnostics solutions, generating revenue mainly from recurring sales of instruments, consumables, reagents and related services to pharmaceutical, biotech, academic and healthcare customers.

Insider activity and ownership structure

For an NYSE-listed issuer like Revvity, insider trading disclosures on Form 4 represent a central element of the governance framework, as they document share purchases, sales and equity award exercises by directors and executive officers, typically within two business days of the transaction date under SEC rules.

Recent regulatory filings in the U.S. market provide an ongoing record of insider dealings and changes in beneficial ownership at comparable life sciences toolmakers and medical technology names, and investors apply the same interpretative framework when they analyze Revvity's own insider reports, looking for patterns such as clustered buying, stock option exercises around vesting dates, or periodic sales aligned with pre-arranged trading plans.

Alongside board and management transactions, ownership disclosures such as Schedule 13D and 13G filings can highlight when institutional investors, hedge funds or strategic partners cross key thresholds such as 5 percent of outstanding shares, offering further transparency into which types of shareholders hold significant influence over voting outcomes at the annual general meeting and potential corporate actions.

Institutional investors, including U.S. mutual funds and pension managers, typically account for a substantial portion of the free float for U.S.-listed life sciences issuers, and Revvity is no exception as it sits in the portfolios of sector-focused and diversified equity funds that benchmark themselves against major U.S. indices and healthcare sub-indices.

Insider and major-holder filings are therefore monitored not only for single large trades, but also for the broader signal they may send about management’s long-term alignment with shareholders, the presence of activist or long-horizon investors, and the potential for strategic initiatives such as portfolio optimization, M&A transactions or capital return programs.

Conclusion

Revvity shares remain anchored around the USD 100 level on the New York Stock Exchange, with trading reflecting the broader backdrop for U.S. life sciences and diagnostics names rather than a single company-specific catalyst in the latest session.

For investors, insider activity and ownership disclosures continue to serve as an important complement to fundamental analysis, offering additional insight into how executives and major shareholders position themselves over time.

As the company advances its portfolio of laboratory tools and diagnostic offerings, the interplay between strategic initiatives, sector dynamics and the behavior of key insiders and institutional holders is likely to remain a focal point for market participants assessing the stock.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.